Document Detail


Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin.
MedLine Citation:
PMID:  2720925     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To investigate the effect of Kawasaki syndrome on myocardial function, as well as the influence of high-dose intravenous gamma-globulin therapy on resolution of functional abnormalities, we studied 98 patients with Kawasaki syndrome during five time intervals from onset of illness: 1) 10 days or less, 2) 11-31 days, 3) 1-3 months, 4) 3-12 months, and 5) 1-3 years. Normal controls included 48 children under age 8 years, without known cardiovascular disease. Using two-dimensional directed M-mode echocardiograms, we obtained chamber dimensions, fractional shortening, rate-corrected velocity of shortening (Vcfc) adjusted for end-systolic wall stress, and early diastolic function parameters that included adjusted peak rates of left ventricular dimension change, wall thinning, and their respective timing. Left ventricular systolic and diastolic dimensions were larger (both p less than 0.01) in patients than in normal subjects in period 1. Stress-adjusted Vcfc was much lower in patients in the 3 months after disease onset; by period 5, contractility was comparable in patients and normal subjects. Adjusted indexes of early diastolic function did not differ significantly between patients and normal subjects. To investigate the effect of gamma-globulin, we analyzed data on 47 patients prospectively randomized to therapy with aspirin alone (n = 19, 40%) or to aspirin plus gamma-globulin, 400 mg/kg/day for 4 consecutive days (n = 28, 60%). In period 1, before treatment, the two groups had mean fractional shortening and stress-adjusted Vcfc comparable to each other but much lower than those of normal subjects (p less than or equal to 0.001). Patients treated with aspirin alone continued to have diminished fractional shortening and Vcfc compared with normal subjects in periods 2, 3, and 4 (all p less than or equal to 0.05). In contrast, fractional shortening and Vcfc in gamma-globulin-treated patients in these periods were comparable to those of normal subjects. By period 5, no difference was detected in systolic function or contractility between either treatment group and normal subjects. We conclude that early abnormalities of left ventricular contractility and myocardial function, as assessed by echocardiography, generally resolve by 1-3 years after disease onset and that recovery is accelerated by administration of IVGG in the acute phase.
Authors:
J W Newburger; S P Sanders; J C Burns; I A Parness; A S Beiser; S D Colan
Related Documents :
17726625 - Transthoracic echo-doppler assessment of coronary microvascular function late after kaw...
19906455 - Atrial interaction in the form of 'cross talk' in patients with ventricular outflow tra...
12528765 - Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and d...
23842075 - Ischemia-guided percutaneous coronary intervention for patients with stable coronary ar...
22608895 - Percutaneous device closure of atrial septal defect results in very early and sustained...
15030425 - Catheter ablation of ventricular tachycardia by intramyocardial injection of ethanol in...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  79     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1989 Jun 
Date Detail:
Created Date:  1989-07-07     Completed Date:  1989-07-07     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1237-46     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, Children's Hospital, Boston, MA 02115.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / therapeutic use*
Child
Echocardiography
Female
Follow-Up Studies
Humans
Immunization, Passive*
Male
Mucocutaneous Lymph Node Syndrome / physiopathology*,  therapy
Myocardial Contraction*
Prospective Studies
Random Allocation
Time Factors
Grant Support
ID/Acronym/Agency:
HL-33836/HL/NHLBI NIH HHS; HL-34545/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac conduction abnormalities during percutaneous balloon mitral or aortic valvotomy.
Next Document:  Assessment of ventricular contractile state and function in patients with univentricular heart.